BiomX Inc. announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis ("CF") during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference (ECFC), which is being held June 7-10th, 2023, in Vienna, Austria. The Phase 1b/2a data will also be presented as a poster at the conference; posters will be located in Foyers E and F on Level 0. Details of the oral presentation are as follows: Title: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aerUGinosa pulmonary infection. Abstract: P095 Workshop 15 - Late-Breaking Science.

Date and Time: June 9, 2023, 17:00-17:30 CEST. Presenter: Dr. Urania Rappo, BiomX Inc., Cambridge, United States.